<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372959">
  <stage>Registered</stage>
  <submitdate>17/05/2017</submitdate>
  <approvaldate>8/06/2017</approvaldate>
  <actrnumber>ACTRN12617000845336</actrnumber>
  <trial_identification>
    <studytitle>The effect of insulin on blood flow to the heart during a heart attack.</studytitle>
    <scientifictitle>The effect of hyperinsulinemic euglycemia on myocardial blood flow reserve in patients with obstructive coronary artery disease</scientifictitle>
    <utrn />
    <trialacronym>EHEMI</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myocardial infarction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous administration of rapid-acting human insulin (rDNA) 1.5mU/kg/minute for 2 hours with concurrent administration of 25% glucose intravenously (dose titrated according to blood glucose aiming for a blood glucose within 10% baseline and greater than 4mmol/L). 
</interventions>
    <comparator>Usual guideline-directed care as per European Society of Cardiology and American College of Cardiology national guidelines.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Perfusion defect size assessed on myocardial contrast echocardiography.</outcome>
      <timepoint>24 hours post-treatment commencement.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial blood flow to remote non-ischaemic myocardial territories measured using myocardial contrast echocardiography.</outcome>
      <timepoint>24 hours post-treatment commencement.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ECG ST segment resolution.
</outcome>
      <timepoint>ECG analysis at 30 minutes, 60 minutes, 120 minutes, and 24 hours after primary percutaneous coronary intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aged 18-80
Acute ST elevation myocardial infarction planned for primary percutaneous coronary intervention for mechanical revascularisation OR emergent percutaneous coronary intervention for failed pharmacological thrombolysis.
Able to provide written informed consent.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous coronary or cardiac valvular intervention.
On insulin therapy.
Cardiogenic shock.
Malignant life-threatening illness.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Dice rolling.</concealment>
    <sequence>Simple randomisation.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Comparison of mean change in outcome measures using student t-test of wilcoxin test.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/10/2016</actualstartdate>
    <anticipatedenddate>17/08/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/08/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Sunshine Coast University Hospital - Birtinya</hospital>
    <postcode>4575 - Birtinya</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sunshine Coast University Hospital</primarysponsorname>
    <primarysponsoraddress>Sunshine Coast University Hospital
6 Doherty Street, 
Birtinya 
Qld 4575</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Wishlist Grant</fundingname>
      <fundingaddress>Sunshine Coast University Hospital
6 Doherty Street, 
Birtinya 
Qld 4575</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novonordisk</fundingname>
      <fundingaddress>Novonordisk headquarters
Level 3/ 21 Solent Circuit, Baulkham Hills New South Wales 2153</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Queensland</othercollaboratorname>
      <othercollaboratoraddress> University of Queensland School of Medicine
Head Office - 288 Herston Road
Herston 
Queensland 4006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Sunshine Coast</othercollaboratorname>
      <othercollaboratoraddress>University of Sunshine Coast
90 Sippy Downs Drive 
Sippy Downs 
Queensland 4556
</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The effect of hyperinsulinemic euglycaemia (HE) on myocardial ischaemia is unknown. We have previously shown that HE increases myocardial blood flow in healthy individuals. We speculate that following successful revascularisation of a myocardial infarction, HE can improve microvascular flow to both ischaemic and remote non-ischaemic myocardial territories. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metro South Human Research Ethics Committee</ethicname>
      <ethicaddress>PAH Centres for Health Research
Level 7, Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102</ethicaddress>
      <ethicapprovaldate>11/08/2015</ethicapprovaldate>
      <hrec>HREC/15/QPAH/386</hrec>
      <ethicsubmitdate>31/07/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Michael Chi Yuan Nam</name>
      <address>Sunshine Coast University Hospital
6 Doherty Street, 
Birtinya 
Qld 4575</address>
      <phone>+61401946407</phone>
      <fax />
      <email>michael.nam@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Nam</name>
      <address>Sunshine Coast University Hospital
6 Doherty Street, 
Birtinya 
Qld 4575</address>
      <phone>+61401946407</phone>
      <fax />
      <email>michael.nam@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Nam</name>
      <address>Sunshine Coast University Hospital
6 Doherty Street, 
Birtinya 
Qld 4575</address>
      <phone>+61401946407</phone>
      <fax />
      <email>michael.nam@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>